Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from AngioDynamics ( (ANGO) ) is now available.
AngioDynamics reported strong financial results for the first quarter of fiscal year 2026, ending August 31, 2025, with a 12.2% increase in net sales to $75.7 million. The Med Tech segment saw a 26.1% growth, driven by platforms such as Auryon, AngioVac, and NanoKnife. The company also achieved significant clinical milestones, including the enrollment of the first patients in the AMBITION BTK and RECOVER-AV trials, and the publication of the NanoKnife PRESERVE study results in a leading journal. These developments underscore AngioDynamics’ commitment to advancing clinical evidence and expanding its market presence.
The most recent analyst rating on (ANGO) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on AngioDynamics stock, see the ANGO Stock Forecast page.
Spark’s Take on ANGO Stock
According to Spark, TipRanks’ AI Analyst, ANGO is a Neutral.
AngioDynamics faces financial challenges with declining revenues and negative cash flows. However, strong earnings call performance, increased guidance, and strategic corporate events indicate potential for future growth. Valuation remains a concern due to negative earnings and no dividend yield.
To see Spark’s full report on ANGO stock, click here.
More about AngioDynamics
AngioDynamics, Inc. is a leading medical technology company focused on restoring healthy blood flow in the vascular system, expanding cancer treatment options, and improving quality of life for patients.
Average Trading Volume: 534,466
Technical Sentiment Signal: Buy
Current Market Cap: $454.7M
For an in-depth examination of ANGO stock, go to TipRanks’ Overview page.